ANIP · ANI Pharmaceuticals, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ANIP. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ANIP · ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Live Quote
BUY (score +6) · 12-1 mom 23.6% · RSI 57.1 · above_both · -16.1% from high
Targets blend Wall Street consensus (7 analysts: low $100.00 / mean $112.71 / high $124.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Anti-signals (insider selling cluster ~$1.1M and active product recall) trigger the mandatory skip gate. The composite score of 40 falls below the 45 threshold, and the dossier lacks the necessary smart-money confirmation or structural edge to override the selling and quality concerns.
Anti-signals (insider selling cluster ~$1.1M and active product recall) trigger the mandatory skip gate. The composite score of 40 falls below the 45 threshold, and the dossier lacks the necessary smart-money confirmation or structural edge to override the selling and quality concerns.
ANIP triggered on a Form 4 cluster (5+ filings in 14 days), but investigation reveals the cluster consists entirely of routine restricted stock award (RSA) grants to non-employee directors vesting on a scheduled calendar date — no open-market purchases from CEO or CFO. The one officer transaction was the SVP/CFO exercising old options and immediately selling via a pre-set 10b5-1 plan, not a discretionary vote of confidence. Separately, Patrick Walsh (Director) executed two large open-market sales in May (~14k shares at ~$80.63–$80.75), an anti-signal. Q1 earnings beat consensus by +57.8% and management raised full-year 2026 revenue guidance to $1.08B–$1.14B, with Cortrophin Gel growing 42% YoY. The stock trades at only ~9.75x forward earnings despite 20%+ revenue growth and ~7.5% FCF yield — a clear valuation anomaly relative to specialty pharmaceutical peers at 12–18x.